Farmas USA

CLSN S3 y S3A, el segundo entiendo que es una pequeña dilución ATM para hacer efectivos unos warrants antiguos al colocador Hércules, pero del primero no entiendo nada, porque no me consta ningún acuerdo de junio, con lo que no me queda claro si ya han emitido 2,712,188 acciones y les quedan 670,070 para 2016 o es todo un lote nuevo que nos va a pegar un palo que nos va a dejar tiesos.

S3

This prospectus relates to an aggregate of up to 3,382,258 shares of our common stock, par value $0.01 per share, that may be resold from time to time by EGWU, Inc. (formerly known as Egen, Inc.), an Alabama corporation , the selling stockholder identified in this prospectus, including its transferees, donees, pledgees, assignees and successors-in-interest. We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling stockholder. As of the date of this prospectus, 2,712,188 shares are issued and outstanding in connection with the consummation of our acquisition of substantially all of the assets of the selling stockholder on June 20, 2014 pursuant to an asset purchase agreement dated as of June 6, 2014, by and between the selling stockholder and us, and up to 670,070 additional shares are issuable on or after August 2, 2016 pending certain potential adjustments for expenses or i n relation to the selling stockholder’s indemnification obligations under the asset purchase agreement. The selling stockholder may sell all or a portion of the shares directly to purchasers or through underwriters, brokers-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions. These sales may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price, at varying prices determined at the time of sale or at negotiated prices. See the section titled “Plan of Distribution” in this prospectus for a more complete description of the ways in which the shares may be sold. We have agreed to bear the reasonable expenses in connection with the registration of the shares of common stock to be offered by this prospectus by the selling stockholder other than all discounts and selling commissions allocable to the sale of such shares, which will be borne by the selling stockholder.

S3A

This prospectus relates to the resale from time to time of 194,986 shares of our comment stock, par value $0.01 per share, issuable upon exercise of an outstanding warrant by Hercules Technology Growth Capital, Inc . (Hercules), the selling stockholder identified in this prospectus, including its transferees, donees, pledgees, assignees and successors-in-interest. The warrant was issued by us to Hercules on November 25, 2013, in connection with a secured term loan provided by Hercules to us. As of the date of this prospectus, 194,986 shares of common stock are exercisable by the selling stockholder. The selling stockholder may offer and sell the shares in public or private transactions or both. These sales may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices. We are not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale of shares of common stock by the selling stockholder. All shares of our common stock offered by this prospectus are being registered for the account of the selling stockholder. We will not receive any of the proceeds from the sale of these shares. However, we will receive proceeds from the cash exercise of the warrant which, if exercised in cash with respect to all of the 194,986 shares of common stock, would result in gross proceeds of up to $699,999.74 to us. The warrant contains a net exercise provision, pursuant to which, in lieu of payment of the exercise price in cash, the warrant can be surrendered for the issuance of a number of shares of our common stock equal to the product of the number of shares of our common stock requested to be issued pursuant to the exercise multiplied by a fraction, the numerator of which is the then-current fair market value of our common stock minus the exercise price and the denominator of which is the then-current fair market value of our common stock. We intend to use the proceeds from any cash exercise for working capital and general corporate purposes. There is no assurance that the warrant will be exercised at all or exercised in cash. Our authorized capital stock consists of 75,000,000 shares of common stock, $0.01 par value per share, and 100,000 shares of preferred stock, $0.01 par value per share. As of September 15, 2014, there were 19,964,212 shares of our common stock outstanding and no shares of preferred stock outstanding.

Sí, lo primero: 3 inyecciones de 60 con 4 semanas de separación entre una y otra.

Recibieron las tres inyecciones intramusculares durante el tercer trimestre o bien de 60 μg/dosis de vacuna contra el virus respiratorio sincitial junto con su aditivo de 1,2 mg de fosfato de aluminio o bien de solución salina [a modo de placebo deduzco].

ACTCD

Especulación

¿Han bajado el precio de la acción para poder poner las stock options lo más bajo posible y a partir de ahí repuntar?

Se admiten desvaríos sobre stock options, que no controlo.

Thanks :)

Completion of REDUCE-IT Best Way to Maximize Amarin (AMRN) Vascepa L-T Value, Jefferies Says

AMRN

no encuentro el cuerpo de la noticia, seguire buscando

Actcd

Otro desvarío que se me ocurre. No se cómo va el tema de las stock options pero supongo que si Lanza se va las pierde no?. Si es así, entendemos que mientras que no compre es que no se va, no?

ACTCD

Yo supongo que crearán una filial de ACTC y nos darán x acciones de ella a los accionistas y Lanza se irá ahí.

No tengo claro que si se fuera se quedara sin las opciones. Habría que leer el contrato. Lo que está claro es que si le dan acciones y opciones es que sigue dentro.